Next Article in Journal
Mammary Gland Transcriptome and Proteome Modifications by Nutrient Restriction in Early Lactation Holstein Cows Challenged with Intra-Mammary Lipopolysaccharide
Next Article in Special Issue
Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway
Previous Article in Journal
Abdominal Fat SIRT6 Expression and Its Relationship with Inflammatory and Metabolic Pathways in Pre-Diabetic Overweight Patients
Previous Article in Special Issue
Jumping on the Bandwagon: A Review on the Versatile Applications of Gold Nanostructures in Prostate Cancer
Open AccessReview

Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis

by 1,2, 1,2,†, 1,2,†, 1,2 and 1,2,*
1
Australian Prostate Cancer Research Centre—Queensland, Translational Research Institute, 37 Kent St, Brisbane, Queensland 4102, Australia
2
Cancer Program, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Brisbane, Queensland 4059, Australia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(5), 1154; https://doi.org/10.3390/ijms20051154
Received: 18 February 2019 / Accepted: 26 February 2019 / Published: 6 March 2019
Prostate cancer (PCa) is one of the most commonly diagnosed cancers worldwide, accounting for almost 1 in 5 new cancer diagnoses in the US alone. The current non-invasive biomarker prostate specific antigen (PSA) has lately been presented with many limitations, such as low specificity and often associated with over-diagnosis. The dysregulation of miRNAs in cancer has been widely reported and it has often been shown to be specific, sensitive and stable, suggesting miRNAs could be a potential specific biomarker for the disease. Previously, we identified four miRNAs that are significantly upregulated in plasma from PCa patients when compared to healthy controls: miR-98-5p, miR-152-3p, miR-326 and miR-4289. This panel showed high specificity and sensitivity in detecting PCa (area under the curve (AUC) = 0.88). To investigate the specificity of these miRNAs as biomarkers for PCa, we undertook an in depth analysis on these miRNAs in cancer from the existing literature and data. Additionally, we explored their prognostic value found in the literature when available. Most studies showed these miRNAs are downregulated in cancer and this is often associated with cancer progression and poorer overall survival rate. These results suggest our four miRNA signatures could potentially become a specific PCa diagnostic tool of which prognostic potential should also be explored. View Full-Text
Keywords: miRNAs; biomarker; prostate cancer; diagnosis; prognosis miRNAs; biomarker; prostate cancer; diagnosis; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Moya, L.; Meijer, J.; Schubert, S.; Matin, F.; Batra, J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. Int. J. Mol. Sci. 2019, 20, 1154. https://doi.org/10.3390/ijms20051154

AMA Style

Moya L, Meijer J, Schubert S, Matin F, Batra J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. International Journal of Molecular Sciences. 2019; 20(5):1154. https://doi.org/10.3390/ijms20051154

Chicago/Turabian Style

Moya, Leire; Meijer, Jonelle; Schubert, Sarah; Matin, Farhana; Batra, Jyotsna. 2019. "Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis" Int. J. Mol. Sci. 20, no. 5: 1154. https://doi.org/10.3390/ijms20051154

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop